<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>2014 Archivi - Adres</title>
	<atom:link href="https://adreshe.com/category/articoli/2014/feed/" rel="self" type="application/rss+xml" />
	<link>https://adreshe.com/category/articoli/2014/</link>
	<description>Health Economics &#38; Outcomes Research</description>
	<lastBuildDate>Mon, 09 Sep 2024 11:02:41 +0000</lastBuildDate>
	<language>it-IT</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://adreshe.com/wp-content/uploads/2024/06/cropped-Logo-Ad-32x32.png</url>
	<title>2014 Archivi - Adres</title>
	<link>https://adreshe.com/category/articoli/2014/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Comparative pharmaco-economic assessment of apixaban versus standard of care for the prevention of stroke in italian atrial fibrillation patients</title>
		<link>https://adreshe.com/comparative-pharmaco-economic-assessment-of-apixaban-versus-standard-of-care-for-the-prevention-of-stroke-in-italian-atrial-fibrillation-patients/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Sun, 26 Jan 2014 09:45:39 +0000</pubDate>
				<category><![CDATA[2014]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=942</guid>

					<description><![CDATA[<p>Pradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. &#8211; Farmeconomia. Health economics and therapeutic pathways 2014; 15(Suppl 1): 15-25</p>
<p>L'articolo <a href="https://adreshe.com/comparative-pharmaco-economic-assessment-of-apixaban-versus-standard-of-care-for-the-prevention-of-stroke-in-italian-atrial-fibrillation-patients/">Comparative pharmaco-economic assessment of apixaban versus standard of care for the prevention of stroke in italian atrial fibrillation patients</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Pradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. &#8211; Farmeconomia. Health economics and therapeutic pathways 2014; 15(Suppl 1): 15-25</p>
<p>L'articolo <a href="https://adreshe.com/comparative-pharmaco-economic-assessment-of-apixaban-versus-standard-of-care-for-the-prevention-of-stroke-in-italian-atrial-fibrillation-patients/">Comparative pharmaco-economic assessment of apixaban versus standard of care for the prevention of stroke in italian atrial fibrillation patients</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Budget impact analysis of apixaban versus other NOACs for the prevention of stroke in italian atrial fibrillation patients</title>
		<link>https://adreshe.com/budget-impact-analysis-of-apixaban-versus-other-noacs-for-the-prevention-of-stroke-in-italian-atrial-fibrillation-patients/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Sun, 26 Jan 2014 09:45:14 +0000</pubDate>
				<category><![CDATA[2014]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=940</guid>

					<description><![CDATA[<p>Pradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. &#8211; Farmeconomia. Health economics and therapeutic pathways 2014; 15(Suppl 1): 5-14</p>
<p>L'articolo <a href="https://adreshe.com/budget-impact-analysis-of-apixaban-versus-other-noacs-for-the-prevention-of-stroke-in-italian-atrial-fibrillation-patients/">Budget impact analysis of apixaban versus other NOACs for the prevention of stroke in italian atrial fibrillation patients</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Pradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. &#8211; Farmeconomia. Health economics and therapeutic pathways 2014; 15(Suppl 1): 5-14</p>
<p>L'articolo <a href="https://adreshe.com/budget-impact-analysis-of-apixaban-versus-other-noacs-for-the-prevention-of-stroke-in-italian-atrial-fibrillation-patients/">Budget impact analysis of apixaban versus other NOACs for the prevention of stroke in italian atrial fibrillation patients</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cost effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in italian atrial fibrillation patients</title>
		<link>https://adreshe.com/cost-effectiveness-analysis-of-apixaban-versus-other-noacs-for-the-prevention-of-stroke-in-italian-atrial-fibrillation-patients/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Sun, 26 Jan 2014 09:44:45 +0000</pubDate>
				<category><![CDATA[2014]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=938</guid>

					<description><![CDATA[<p>Pradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. &#8211; Farmeconomia. Health economics and therapeutic pathways 2014; 15(4): 101-112</p>
<p>L'articolo <a href="https://adreshe.com/cost-effectiveness-analysis-of-apixaban-versus-other-noacs-for-the-prevention-of-stroke-in-italian-atrial-fibrillation-patients/">Cost effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in italian atrial fibrillation patients</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Pradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. &#8211; Farmeconomia. Health economics and therapeutic pathways 2014; 15(4): 101-112</p>
<p>L'articolo <a href="https://adreshe.com/cost-effectiveness-analysis-of-apixaban-versus-other-noacs-for-the-prevention-of-stroke-in-italian-atrial-fibrillation-patients/">Cost effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in italian atrial fibrillation patients</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cost-effectiveness of blood culture and a multiplex real-time pcr in hematological patients with suspected sepsis: an observational propensity score-matched study</title>
		<link>https://adreshe.com/cost-effectiveness-of-blood-culture-and-a-multiplex-real-time-pcr-in-hematological-patients-with-suspected-sepsis-an-observational-propensity-score-matched-study/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Sun, 26 Jan 2014 09:44:14 +0000</pubDate>
				<category><![CDATA[2014]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=936</guid>

					<description><![CDATA[<p>Mancini N, Sambri V, Corti C, Ghidoli N, Tolomelli G, Paolucci M, Clerici D, Carletti S, Greco R, Tassara M, Pizzorno B, Zaniolo O, Povero M, Pradelli L, Burioni R, Stanzani M, Landini MP, Ciceri F, Clementi M. &#8211; Expert Rev Mol Diagn 2014; 14(5): 623-32</p>
<p>L'articolo <a href="https://adreshe.com/cost-effectiveness-of-blood-culture-and-a-multiplex-real-time-pcr-in-hematological-patients-with-suspected-sepsis-an-observational-propensity-score-matched-study/">Cost-effectiveness of blood culture and a multiplex real-time pcr in hematological patients with suspected sepsis: an observational propensity score-matched study</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Mancini N, Sambri V, Corti C, Ghidoli N, Tolomelli G, Paolucci M, Clerici D, Carletti S, Greco R, Tassara M, Pizzorno B, Zaniolo O, Povero M, Pradelli L, Burioni R, Stanzani M, Landini MP, Ciceri F, Clementi M. &#8211; Expert Rev Mol Diagn 2014; 14(5): 623-32</p>
<p>L'articolo <a href="https://adreshe.com/cost-effectiveness-of-blood-culture-and-a-multiplex-real-time-pcr-in-hematological-patients-with-suspected-sepsis-an-observational-propensity-score-matched-study/">Cost-effectiveness of blood culture and a multiplex real-time pcr in hematological patients with suspected sepsis: an observational propensity score-matched study</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cost-effectiveness of omega-3 fatty acid supplements in parenteral nutrition therapy in hospitals: a discrete event simulation model</title>
		<link>https://adreshe.com/cost-effectiveness-of-omega-3-fatty-acid-supplements-in-parenteral-nutrition-therapy-in-hospitals-a-discrete-event-simulation-model/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Sun, 26 Jan 2014 09:43:37 +0000</pubDate>
				<category><![CDATA[2014]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=934</guid>

					<description><![CDATA[<p>Pradelli L, Eandi M, Povero M, Mayer K, Muscaritoli M, Heller AR, Fries-Schaffner E. &#8211; Clin Nutr 2014; 33(5): 785-92</p>
<p>L'articolo <a href="https://adreshe.com/cost-effectiveness-of-omega-3-fatty-acid-supplements-in-parenteral-nutrition-therapy-in-hospitals-a-discrete-event-simulation-model/">Cost-effectiveness of omega-3 fatty acid supplements in parenteral nutrition therapy in hospitals: a discrete event simulation model</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Pradelli L, Eandi M, Povero M, Mayer K, Muscaritoli M, Heller AR, Fries-Schaffner E. &#8211; Clin Nutr 2014; 33(5): 785-92</p>
<p>L'articolo <a href="https://adreshe.com/cost-effectiveness-of-omega-3-fatty-acid-supplements-in-parenteral-nutrition-therapy-in-hospitals-a-discrete-event-simulation-model/">Cost-effectiveness of omega-3 fatty acid supplements in parenteral nutrition therapy in hospitals: a discrete event simulation model</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Real-life cost and cost-effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48-month survey</title>
		<link>https://adreshe.com/real-life-cost-and-cost-effectiveness-for-tiotropium-18-%ce%bcg-od-monotherapy-in-moderate-and-severe-copd-patients-a-48-month-survey/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Sun, 26 Jan 2014 09:42:51 +0000</pubDate>
				<category><![CDATA[2014]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=932</guid>

					<description><![CDATA[<p>Povero M, Pradelli L, Turco P, Dal Negro RW. &#8211; Farmeconomia. Health economics and therapeutic pathways 2014; 15(2): 39-44</p>
<p>L'articolo <a href="https://adreshe.com/real-life-cost-and-cost-effectiveness-for-tiotropium-18-%ce%bcg-od-monotherapy-in-moderate-and-severe-copd-patients-a-48-month-survey/">Real-life cost and cost-effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48-month survey</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Povero M, Pradelli L, Turco P, Dal Negro RW. &#8211; Farmeconomia. Health economics and therapeutic pathways 2014; 15(2): 39-44</p>
<p>L'articolo <a href="https://adreshe.com/real-life-cost-and-cost-effectiveness-for-tiotropium-18-%ce%bcg-od-monotherapy-in-moderate-and-severe-copd-patients-a-48-month-survey/">Real-life cost and cost-effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48-month survey</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>The economic impact associated with cerebrovascular events related to non-valvular atrial fibrillation (NVAF) in Italy: the role of apixaban</title>
		<link>https://adreshe.com/the-economic-impact-associated-with-cerebrovascular-events-related-to-non-valvular-atrial-fibrillation-nvaf-in-italy-the-role-of-apixaban/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Wed, 01 Jan 2014 09:59:00 +0000</pubDate>
				<category><![CDATA[2014]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=4956</guid>

					<description><![CDATA[<p>Pradelli L., Calandriello M., Di Virgilio R., Bellone M., Tubaro M. – Farmeconomia. Health economics and therapeutic pathways 2014; 15(1S): 3-4</p>
<p>L'articolo <a href="https://adreshe.com/the-economic-impact-associated-with-cerebrovascular-events-related-to-non-valvular-atrial-fibrillation-nvaf-in-italy-the-role-of-apixaban/">The economic impact associated with cerebrovascular events related to non-valvular atrial fibrillation (NVAF) in Italy: the role of apixaban</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Pradelli L., Calandriello M., Di Virgilio R., Bellone M., Tubaro M. – Farmeconomia. Health economics and therapeutic pathways 2014; 15(1S): 3-4</p>
<p>L'articolo <a href="https://adreshe.com/the-economic-impact-associated-with-cerebrovascular-events-related-to-non-valvular-atrial-fibrillation-nvaf-in-italy-the-role-of-apixaban/">The economic impact associated with cerebrovascular events related to non-valvular atrial fibrillation (NVAF) in Italy: the role of apixaban</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
